Canfosfamide hydrochloride: Oncolytic DNA alkylating drug

Drugs of the Future

Volumn 29, Issue 10, 2004, Pages 985-991

  McIntyre, J A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTIEMETIC AGENT; CANFOSFAMIDE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P1 1; IRINOTECAN; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER DISEASE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DNA ALKYLATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HEMATURIA; HUMAN; HYPOKALEMIA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; NAUSEA; NONHUMAN; OVARY CANCER; PANCREATITIS; SOLID TUMOR;

EID: 11144230983     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.10.852956     Document Type: Article

References (47)

1. Lyttle, M.H., Hocker, M.D., Hui, H.C., Caldwell, C.G., Aaron, D.T., Engqvist-Goldstein, A., Flatgaard, J.E., Bauer, K.E. Isozyme-specific glutathione-S-transferase inhibitors: Design and synthesis. J Med Chem 1994, 37: 189-94.
2. Lyttle, M.H., Satyam, A., Hocker, M.D., Bauer, K.E., Caldwell, C.G., Hui, H.C., Morgan, A.S., Mergia, A., Kauvar, L.M. Glutathione-S-transferase activates novel alkylating agents. J Med Chem 1994, 37: 1501-7.
3. Kauvar, L.M., Lyttle, M.H., Satyam, A. (Telik, Inc.). Glutathione S-transferase-activated cpds. CA 2173130, EP 0721465, WO 9509866.
4. Howie, A.F., Forrester, L.M., Glancey, M.J., Schlager, J.J., Powls, G., Beckett, G.J., Hayes, J.D., Wolf, C.R. Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues. Carcinogenesis 1990, 11: 451-8.
5. Tew, K.D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994, 54: 4313-20.
6. Hayes, J.D., Pulford, D.J. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995, 30: 445-600.
7. Farmer, G. Targeted lung cancer therapies. Nat Rev Drug Discov 2004, 3: 547-8.
8. Beroza, P., Meng, F., Bearss, D.J. et al. Efficient discovery of novel small molecule cancer drugs using Telik's target-related affinity profiling (TRAP™) technology. Proc Am Assoc Cancer Res 2002, 43: Abst 191.
9. Satyam, A., Hocker, M.D., Kane-Maguire, K.A., Morgan, A.S., Villar, H.O., Lyttle, M.H. Design, synthesis, and evaluation of latent alkylating agents activated by glutathione S-transferase. J Med Chem 1996, 39: 1736-47.
10. Rosario, L.A., O'Brien, M.L., Henderson, C.J., Wolf, C.R., Tew, K.D. Cellular response to a glutathione S-transferase P1-1 activated prodrug. Mol Pharmacol 2000, 58: 167-74.
11. Tew, K.D. The influence of GST-targeted drugs on cell proliferation and stress response. Chem-Biol Interact 2001, 133: 295-300.
12. Rosario, L.A., O'Brien, M.L., Schow, S.R., Henderson, C.L., Wolf, C.R., Tew, K.D. Preclinical studies with a glutathione S-transferase P1-1 (GSTP1-1) activated prodrug. Clin Cancer Res 2000, 6(Suppl.): Abst 114.
13. Rosario, L.A., O'Brien, M., Tew, K.D. Forced expression of GSTP1-1, γGCS and MRP influences the cytotoxicity to TER286, a GST P1-1 activated prodrug. Proc Am Assoc Cancer Res 2000, 41: Abst 4841.
14. Morgan, A.S., Sanderson, P.E., Borch, R.F., et al. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. Cancer Res 1998, 58: 2568-75.
15. Izbicka, E., Lawrence, R., Cerna, C., Von Hoff, D.D., Sanderson, P.E. Activity of TER286 against human tumor colony-forming units. Anti-Cancer Drugs 1997, 8: 345-8.
16. Degen, D., Ortiz, V., Cerna, C., Von Hoff, D.D., Sanderson, P. Activity of TER 286 against human tumor colony forming units. 6th Annu Symp Cancer Res (July 26, San Antonio) 1996, Abst 25.
17. Henner, W.D., Morgan, A.S., Von Hoff, D.D., Niitsu, Y., Mannervik, B. Activity of TER286, a cytotoxin activated by glutathione S-transferase against human tumor cell lines, xenografts in mice and primary human tumor cultures. Proc Am Assoc Cancer Res 1998, 39: Abst 2898.
18. Meng, F., Brown, G.L., Keck, J.G., Henner, W.D., Schow, S., Gomez, R.F., Wick, M.M. TLK286-induced activation of JNK-dependent apoptotic signaling pathway. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Oct 29-Nov 2, Miami Beach) 2001, Abst 326.
19. Meng, F., Kim, S., Brown, G.L., Keck, J.G., Henner, W.D., Schow, S.R., Gomez, R.F., Wick, M.M. TLK286-induced activation of the stress response apoptotic signaling pathway. Proc Am Assoc Cancer Res 2002, 43: Abst 4772.
20. Xu, H., Roth, E., Laborde, E., Schow, S., Gomez, R., Wick, M., Keck, J.G. TLK286 (Telcyta™): Mechanism of induction of apoptosis in human cancer cells. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst C141.
21. Townsend, D.M., Shen, H., Staros, A.L., Gate, L., Tew, K.D. Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells. Mol Cancer Ther 2002, 1: 1089-95.
22. Townsend, D.M., Shen, H., Staros, A., Tew, K.D. Efficacy of a glutathione S-transferase P1-1 activated prodrug in platinum resistant ovarian cancer. Proc Am Assoc Cancer Res 2002, 43: Abst 1284.
23. Keck, J., Meng, F., Grossman, E., Cai, D., Brown, G., Schow, S., Xu, H. Enhanced antitumor activity of TLK286 in combination with carboplatin, doxorubicin and docetaxel in human ovarian and breast cancer cell lines. Eur J Cancer 2002, 38(Suppl. 7): Abst 102.
24. Xu, H., Namgoong, S.-Y., Roth, E., Brown, G.L., Keck, J.G. Synergistic effect of Telcyta™ (TLK286) in combination with paclitaxel, doxorubicin, carboplatin, oxaliplatin, cisplatin, docetaxel, gemcitabine and Iressa in human cancer cells. Proc Am Assoc Cancer Res 2004, 45: Abst 2008.
25. Xu, H., Namgoong, S.-Y., Roth, E., Tran, V., Schow, S., Brown, G.L., Keck, J.G. Synergistic cancer cell cytotoxicity of TLK286 (Telcyta™) in combination with carboplatin, cisplatin, doxorubicin, docetaxel, paclitaxel or oxaliplatin in human ovarian, lung, breast and colorectal cancer cell lines. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst C156.
26. Garzone, P.D. In vitro and in vivo pharmacokinetic characterization of TLK286 (Telcyta™), a novel anti-tumor agent. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst C242.
27. Rosen, L.S., Brown, J., Laxa, B. et al. Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies. Clin Cancer Res 2003, 9: 1628-38.
28. Rosen. L.S., Kadib, L., Laxa, B., Brown, J., Kilfoil, G., Gomez, R., Wick, M., Vollmer, C., Brown, G. TLK286: Phase I dose-escalation trial in patients with advanced malignancies. Clin Cancer Res 2000, 6(Suppl.): Abst 201.
29. Brown, G.L., Lum, R.T., Schow, S.R. et al. TLK286: Phase I dose escalation trial in patients with advanced malignancies. Proc Am Soc Clin Oncol 2001, 20(Part 1): Abst 483.
30. Rosen, L.S., Laxa, B., Boulos, L., Wiggins, L., Keck, J.G., Jameson, A.J., Parra, R., Patel, K., Brown, G.L. Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies. Clin Cancer Res 2004, 10: 3689-98.
31. Rosen. L.S., Kadib, L., Laxa, B. et al. Phase I study of TLK286 administered weekly in advanced refractory malignancies. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Oct 29-Nov 2, Miami Beach) 2001, Abst 294.
32. Brown, G.L., Boulos, L., Reiswig, L. et al. Phase I TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with advanced malignancies. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 345.
33. Kavanagh, J.J., Kudelka, A.P., Gershenson, D.M. et al. Phase 2 study of TLK286 (Telcyta™, a GSTP1-1 activated glutathione analog) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Annu Meet Women's Cancer (Feb 7-11, San Diego) 2004, Abst.
34. Kavanagh, J.J., Kudelka, A.P., Lewis, L., Spriggs, D.R., Bookman, M.A., Brown, S., Maack, C., Dombroski, J., Macpherson, J., Henner, W.D., Brown, G.L. TLK286: Phase 2 study in patients with platinum resistant ovarian cancer. Cancer Invest 2003, 21(Suppl. 1): Abst 69.
35. Kavanagh, J.J., Kudelka, A., Spriggs, D.R., Bookman, M.A., Lewis, L., Maack, C., Dombroski, J., Macpherson, J., Henner, W.D., Brown, G.L. Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) in patients with platinum and paclitaxel refractory/resistant advanced epithelial ovarian cancer. Eur J Cancer 2002, 38(Suppl. 7): Abst 100.
36. Kavanagh, J.J., Kudelka, A.P., Garcia, A., Lewis, L., Bolanos-Clark, M., Maack, C., James, A. Henner, W.D., Brown, G.L. Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with platinum refractory or resistant third-line advanced ovarian cancer. Proc Am Soc Clin Oncol 2003, 22: Abst 1816.
37. Brown, G.L., Lewis, L., Choi, H., Iyer, R., Moore, C., Valmonte, A., Jameson, A., Keck, J., Patel, K., Kavanagh, J. Phase 1-2a dose ranging study of TLK286 (a novel glutathione analog) in combination with liposomal doxorubicin in platinum refractory or resistant ovarian cancer. 40th Annu Meet Am Soc Clin Oncol (June 5-8, New Orleans) 2004, Abst 5062.
38. Kudelka, A., Kavanagh, J., Lewis, L. et al. Phase 1-2a dose ranging study of TLK286 (Telcyta™, a novel glutathione analog) in combination with Doxil in platinum refractory or resistant ovarian cancer. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst C139.
39. Kavanagh, J.J., Kudelka, A., Lewis, L. et al. Phase 1-2a study of TLK286 (Telcyta™, a novel glutathione analog) in combination with carboplatin in platinum refractory or resistant (3rd line or more) ovarian cancer. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 17-21, Boston) 2003, Abst C155.
40. Rosen, L.S., Dragovich, T., Lenz, H.J., Lin, E., Wiggins, L., Brown, G.L., Maack, C., Macpherson, J., Dombroski, J., Henner, W.D. Phase II study of TLK286 (glutathione analog activated by GST P1-1) in refractory colorectal cancer. Eur J Cancer 2002, 38(Suppl. 7): Abst 101.
41. Papadimitrakopoulou, V., Figlin, R., Garland, L., Von Hoff, D., Kris, M., Purdom, M., Brown, G.L., Maack, C., Macpherson, J., Henner, W.D. Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) in patients with non-small cell lung cancer who failed prior platinum-based regimens. Eur J Cancer 2002, 38(Suppl. 7): Abst 106A.
42. Papadimitrakopoulou, V., Fligin, R., Garland, L., Blumenschein, G., Fossella, F., Von Hoff, D.D., King, L., Brown, G.L., Mascavage, J., Henner, W.D. Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with non-small cell lung cancer (NSCLC) who failed prior platinum-based regimens. Proc Am Soc Clin Oncol 2003, 22: Abst 2636.
43. Papadimitrakopoulou, V., Boasberg, P., Figlin, R., Zinner, R., Blumenschein, G., King, L., Truong, M., Patel, K., Brown, G.L., Hanna, N. Phase 1-2a dose ranging study of TLK286 (a novel glutathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer (NSCLC). 40th Annu Meet Am Soc Clin Oncol (June 5-8, New Orleans) 2004, Abst 7140.
44. Washington, D., Miller, K., Budd, G.T., Taylor, C., Von Hoff, D.D., Brown, G.L., Parra, R., Jameson, A., Mascavage, J., Henner, W.D. Phase 2 study of TLK286 (GSTP1-1 activated glutathione analog) as third-line therapy in patients with advanced metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2003, 22: Abst 61.
45. Telik reveals R&D highlights during the first quarter. DailyDrugNews.com (Daily Essentials) May 16, 2003.
46. Telik highlights Q1 developments. DailyDrugNews.com (Daily Essentials) June 1, 2004.
47. Telcyta™. Telik Web Site October 7, 2004.